MedTrace Logo

A Study of XS-02 Capsules in Patients With Advanced Solid Tumors

NCT06531486 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2024-08-01

No results posted yet for this study

Summary

A study to evaluate the safety, tolerability, Pharmacokinetics(pk), and efficacy of XS-02 capsules in patients with advanced solid tumors.

Conditions

Interventions

OTHER

XS-02 capsules

Upon completion of all screening visits, eligible patients will be treated with XS-02 capsules at the appropriate dose.

Sponsors & Collaborators

  • NovaOnco Therapeutics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-29
Primary Completion
2027-02-28
Completion
2027-08-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06531486 on ClinicalTrials.gov